LFG316

A complement C5-blocking mAb.

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

LFG316 is a patented (US8241628) experimental monoclonal antibody drug targeting C5 complement factor (DrugBank).

Tesidolumab

Link	Tested on	Impact factor	Notes	Publication date
Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19 Critical severity Case series Antibody	Patients	17.45	Clinical improvement in the majority of critically ill mechanically ventilated “proned” patients. Sample size: 5. Dosage: A single 1500mg infusion.	Sep/08/2020